Deutsche Bank initiated coverage of Xenon Pharmaceuticals (XENE) with a Buy rating and $67 price target
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Positive Long-Term Outlook for Xenon Pharmaceuticals Amid Anticipated Epilepsy Data Event
- Xenon Pharmaceuticals’ CCO Departure and Consultancy Role
- Xenon Pharmaceuticals Sets Sights on Key 2025 Milestones
- Xenon Pharmaceuticals outlines key corporate milestone opportunities for 2025
- Xenon to Showcase Innovations at J.P. Morgan Healthcare Conference